News

News By Year: All | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

09 Apr 2026 Evolve Capital’s Equity Research – No Clear Catalysts, FY26 Recovery a Low-Bar Normalisation
05 Mar 2026 PhillipCapital’s Equity Research – Hit the Refresh Button
03 Sep 2025 Evolve Capital’s Equity Research – 1H2025: Near Term Performance Likely to Remain Subdued Before Modest Recovery
25 Aug 2025 PhillipCapital’s Equity Research – 1H2025: Bump in the Road, Scaling Up Journey Intact
20 Aug 2025 CGS International’s Equity Research – 1H2025 In the Midst of Product Portfolio Review
03 Apr 2025 Evolve Capital’s Equity Research – Initiating Coverage: Decent Fundamentals, Weak Valuations
10 Mar 2025 SAC Capital’s Equity Research – FY2024: Strong Growth Momentum
03 Mar 2025 CGS International’s Equity Research – Reinvesting for Growth in FY25F
13 Nov 2024 CGS International’s Equity Research – 3Q2024: Slowing Revenue Momentum
11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International’s Equity Research: Positive Revenue Momentum in 1Q24
13 Mar 2024 CGS International’s Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB’s Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
09 Nov 2023 The Edge Singapore: Hyphens Pharma’s high returns to shareholders fuelled by a post-pandemic boom, accretive acquisition
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
17 Oct 2023 The Edge Singapore: Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB’s Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
30 Jan 2023 The Business Times – Hyphens Pharma to expand footprint in Southeast Asia: CEO
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
25 Aug 2022 联合早报 – 善用传统学养与数码能力首创综合式医疗科技平台
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
27 May 2022 InvestingNote – An Investor’s Analysis on Hyphens Pharma International Limited
27 May 2022 The Business Times – Hyphens Pharma to sell 10% stake in digital healthtech unit to Metro for S$6m
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
13 Jan 2022 The Straits Times – First HSA-registered e-pharmacy in Singapore launched
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
18 Jan 2021 The Business Times – Hyphens Pharma to expand presence in South Korea through distribution agreement with JSPharma
08 Jan 2021 Singapore Business Review – Hyphens Pharma subsidiary granted e-pharmacy license
07 Jan 2021 The Edge Singapore – Hyphens Pharma awarded e-pharmacy licence for WellAway Pharmacy
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
11 Sep 2020 The Edge Singapore – Hyphens Pharma enjoys lift from broader product range and wider distribution channels
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
28 Jul 2020 Why Intangible Assets Matter
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
25 May 2020 The Business Times – Hyphens Pharma revs up digital push amid Covid-19
21 May 2020 SmallCapAsia – Hyphens Pharma: 5 things I like about the company
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
04 Feb 2020 IPOS and SGX Launch Pilot Programme to Help Companies Identify and Communicate Intangible Assets Information
08 Dec 2019 The Straits Times – Aiming to be Asia’s No. 1 skin-health firm
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
16 May 2019 Investor-One – Hyphens Pharma: A scalable business that rides on regional megatrends
16 May 2019 Investor-One – Hyphens Pharma’s CEO Lim See Wah tells us about Hyphens’ presence and growth prospects in the region [Video]
10 May 2019 RHB’s 20 Jewels 2019 Edition: Investor-One’s Analysis Of 5 Catalist Stocks
09 May 2019 联合早报 – 兴业研究：估值极低科技与制造业股有望后势看涨
07 May 2019 RHB’s 2019 Top Singapore Small Cap Companies (9th Edition) [PDF]
29 Apr 2019 The Business Times – Hyphens flies Asian flag in pharma industry
26 Apr 2019 SGX – Hyphens Flies Asian Flag in Pharma Industry
22 Apr 2019 联合早报 – 凯帆药剂新总部开幕 许宝琨：本地公司 须持续创新建立竞争优势
28 Mar 2019 SGX – 10 in 10 with Hyphens Pharma International [PDF]
22 Mar 2019 The Business Times – Hyphens inks MOU with A*Star’s A*ccelerate
22 Mar 2019 Berita Mediacorp – Produk-produk baru bagi masalah kulit mungkin diperkenalkan seawal tahun depan
22 Mar 2019 The Straits Times – Innovate for global competitive edge, says Koh Poh Koon
22 Mar 2019 The New Paper – Innovation key to help companies expand: Koh Poh Koon
21 Mar 2019 Channel News Asia – New products in the works for common skin problems
22 Nov 2018 Interview with Lianhe Zaobao
09 Apr 2026 Evolve Capital’s Equity Research – No Clear Catalysts, FY26 Recovery a Low-Bar Normalisation
05 Mar 2026 PhillipCapital’s Equity Research – Hit the Refresh Button
03 Sep 2025 Evolve Capital’s Equity Research – 1H2025: Near Term Performance Likely to Remain Subdued Before Modest Recovery
25 Aug 2025 PhillipCapital’s Equity Research – 1H2025: Bump in the Road, Scaling Up Journey Intact
20 Aug 2025 CGS International’s Equity Research – 1H2025 In the Midst of Product Portfolio Review
03 Apr 2025 Evolve Capital’s Equity Research – Initiating Coverage: Decent Fundamentals, Weak Valuations
10 Mar 2025 SAC Capital’s Equity Research – FY2024: Strong Growth Momentum
03 Mar 2025 CGS International’s Equity Research – Reinvesting for Growth in FY25F
13 Nov 2024 CGS International’s Equity Research – 3Q2024: Slowing Revenue Momentum
11 Sep 2024 CGS International Equity Research – 1H2024: Healthy Pipeline of New Products
22 Aug 2024 SAC Capital’s Equity Research – 1H2024: Commendable Growth Amid Economic Headwinds
21 Aug 2024 PhillipCapital’s Equity Research – 1H2024: New Products and Wider Distribution
16 May 2024 SAC Capital’s Equity Research – 1Q2024: Robust Growth Across All Segments
15 May 2024 CGS International’s Equity Research: Positive Revenue Momentum in 1Q24
13 Mar 2024 CGS International’s Equity Research: FY2023 Positive on Expanding Portfolio
27 Nov 2023 CGS-CIMB’s Equity Research: Dented Margins in 3Q23
20 Nov 2023 SAC Capital’s Equity Research – 3Q23 Business Update
09 Nov 2023 The Edge Singapore: Hyphens Pharma’s high returns to shareholders fuelled by a post-pandemic boom, accretive acquisition
20 Oct 2023 SAC Capital’s Equity Research – Pursuing Growth Through Full Acquisition of Ardence Pharma
17 Oct 2023 The Edge Singapore: Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary
22 Aug 2023 PhillipCapital’s Equity Research – Year of Investment and Challenges
18 Aug 2023 Investor-One: What You Need to Know About Hyphens Pharma’s 1H2023 Financial Results
18 Aug 2023 CGS-CIMB’s Equity Research: A Game of Catch-Up for 2H23F
17 Aug 2023 SAC Capital’s Equity Research – Navigating Challenges Amidst Ongoing Improvements
25 May 2023 SAC Capital’s Equity Research – Beyond the Shores
16 May 2023 CGS-CIMB Singapore’s Equity Research – Hit by Supply Chain Disruptions
13 Apr 2023 CGS-CIMB Singapore’s Equity Research – DocMed Undertakes Vietnam Digital Venture
09 Mar 2023 PhillipCapital’s Equity Research – Assembling Multiple Growth Engines
07 Mar 2023 CGS-CIMB Singapore’s Equity Research – FY23F Sets Stage for More Investments
30 Jan 2023 The Business Times – Hyphens Pharma to expand footprint in Southeast Asia: CEO
24 Nov 2022 CGS-CIMB Singapore’s Equity Research – Steadfast in Executing its Business Strategy
28 Aug 2022 PhillipCapital’s Equity Research – Franchise Expands with Acquisitions
25 Aug 2022 联合早报 – 善用传统学养与数码能力首创综合式医疗科技平台
18 Aug 2022 SAC Capital’s Equity Research – Growth from Organic and Acquisition
17 Aug 2022 CGS-CIMB Singapore’s Equity Research – Positioning for Next Phase of Growth
06 Jun 2022 SAC Capital’s Equity Research – Receives S$6m Fund Infusion, Digital Assets Valued at S$60m
06 Jun 2022 PhillipCapital’s Equity Research – Digital Healthcare Catalyst Emerges
27 May 2022 InvestingNote – An Investor’s Analysis on Hyphens Pharma International Limited
27 May 2022 The Business Times – Hyphens Pharma to sell 10% stake in digital healthtech unit to Metro for S$6m
17 May 2022 SAC Capital’s Equity Research – Sterling 1Q22 Backed by Re-Opening Tailwind
13 May 2022 CGS-CIMB Singapore’s Equity Research – Building Up the Hype
04 Apr 2022 KGI Securities’ Equity Research – Novem Acquisition to Boost Top and Bottom-Line Growth
16 Mar 2022 SAC Capital’s Equity Research – Moving in the Right Direction
02 Mar 2022 CGS-CIMB Singapore’s Equity Research – Quality Earnings to Come in FY22F
13 Jan 2022 The Straits Times – First HSA-registered e-pharmacy in Singapore launched
06 Jan 2022 CGS-CIMB Singapore’s Equity Research – On the Lookout for Growth
22 Nov 2021 PhillipCapital’s Equity Research – Speedbump in Vietnam
18 Nov 2021 SAC Capital’s Equity Research – Strategic Acquisition of Novem Group
24 Aug 2021 SAC Capital’s Equity Research – Strongest 1H Recorded
28 Jun 2021 KGI Securities’ Equity Research – A Fresh Start
17 Mar 2021 SAC Capital’s Equity Research – Growing Regional Presence
05 Mar 2021 PhillipCapital’s Equity Research – Not to Be Written Off
18 Jan 2021 The Business Times – Hyphens Pharma to expand presence in South Korea through distribution agreement with JSPharma
08 Jan 2021 Singapore Business Review – Hyphens Pharma subsidiary granted e-pharmacy license
07 Jan 2021 The Edge Singapore – Hyphens Pharma awarded e-pharmacy licence for WellAway Pharmacy
19 Nov 2020 SAC Capital’s Equity Research – Q3 Setback, Longer-Term Growth is Priority
16 Nov 2020 KGI Securities’ Equity Research – Short Term Speed Bump in the Pursuit of Growth
16 Nov 2020 PhillipCapital’s Equity Research – Repositioning for Growth
06 Nov 2020 KGI Securities’ Equity Research – Skin is the game
29 Sep 2020 Lim & Tan Securities’ Equity Research – Special Report
11 Sep 2020 The Edge Singapore – Hyphens Pharma enjoys lift from broader product range and wider distribution channels
31 Aug 2020 SAC Capital’s Equity Research – Broadening Product Range and Footprints
24 Aug 2020 KGI Securities’ Equity Research – A Hair-Raising First Half
20 Aug 2020 PhillipCapital’s Equity Research – Shaking Off COVID-19 Woes with Expanded Portfolio
28 Jul 2020 Why Intangible Assets Matter
20 Jul 2020 PhillipCapital’s Equity Research – Building Channels to Establish Business Longevity
25 May 2020 The Business Times – Hyphens Pharma revs up digital push amid Covid-19
21 May 2020 SmallCapAsia – Hyphens Pharma: 5 things I like about the company
15 May 2020 RHB’s Equity Research – Numbers Improve During Pandemic; Stay BUY
04 Mar 2020 RHB’s Equity Research – Near-Term Outlook Uncertain Due to COVID-19; BUY Maintained
04 Feb 2020 IPOS and SGX Launch Pilot Programme to Help Companies Identify and Communicate Intangible Assets Information
08 Dec 2019 The Straits Times – Aiming to be Asia’s No. 1 skin-health firm
22 Nov 2019 SAC Capital’s Equity Research – 3Q2019 Results Review
20 Nov 2019 RHB’s Equity Research – Banking on Ceradan Products; Keep Buy
08 Nov 2019 SAC Capital’s Equity Research – Healthy Prospects in ASEAN
22 Oct 2019 PhillipCapital’s Equity Research – Leveraging on Trust with Doctors for Profitability
20 Aug 2019 RHB’s Equity Research – Ceradan Leading The Pack; Keep Buy
03 Jul 2019 RHB’s Equity Research – Hyphens Pharma: Undervalued and Under-Covered; Initiate BUY
16 May 2019 Investor-One – Hyphens Pharma: A scalable business that rides on regional megatrends
16 May 2019 Investor-One – Hyphens Pharma’s CEO Lim See Wah tells us about Hyphens’ presence and growth prospects in the region [Video]
10 May 2019 RHB’s 20 Jewels 2019 Edition: Investor-One’s Analysis Of 5 Catalist Stocks
09 May 2019 联合早报 – 兴业研究：估值极低科技与制造业股有望后势看涨
07 May 2019 RHB’s 2019 Top Singapore Small Cap Companies (9th Edition) [PDF]
29 Apr 2019 The Business Times – Hyphens flies Asian flag in pharma industry
26 Apr 2019 SGX – Hyphens Flies Asian Flag in Pharma Industry
22 Apr 2019 联合早报 – 凯帆药剂新总部开幕 许宝琨：本地公司 须持续创新建立竞争优势
28 Mar 2019 SGX – 10 in 10 with Hyphens Pharma International [PDF]
22 Mar 2019 The Business Times – Hyphens inks MOU with A*Star’s A*ccelerate
22 Mar 2019 Berita Mediacorp – Produk-produk baru bagi masalah kulit mungkin diperkenalkan seawal tahun depan
22 Mar 2019 The Straits Times – Innovate for global competitive edge, says Koh Poh Koon
22 Mar 2019 The New Paper – Innovation key to help companies expand: Koh Poh Koon
21 Mar 2019 Channel News Asia – New products in the works for common skin problems
22 Nov 2018 Interview with Lianhe Zaobao